10-Q: Nevro Corp. Reports Mixed Q2 2024 Results Amid Restructuring Efforts

Nevro Corp. experienced a slight revenue decrease in Q2 2024, alongside increased operating expenses and restructuring charges, impacting overall profitability.

Summary

• Nevro Corp.'s revenue for the second quarter of 2024 was $104.2 million, a decrease of 4% compared to $108.8 million in the same period of 2023.
• The company's gross profit decreased to $67.5 million, with a gross margin of 65%, down from 68% in Q2 2023.
• Operating expenses totaled $92.6 million, which included a $4.6 million restructuring charge.
• The net loss for the quarter was $19.6 million, compared to a net loss of $24.7 million in Q2 2023.
• For the first six months of 2024, revenue was $206.1 million, a slight increase from $205.1 million in the same period of 2023.
• The company's net loss for the first six months of 2024 was $45 million, compared to a net loss of $59.8 million for the same period in 2023.
• Nevro's cash, cash equivalents, and short-term investments totaled $273.7 million as of June 30, 2024.
• The company has ongoing minimum annual purchase commitments of $6.3 million for the remainder of 2024 and $4.9 million for 2025.

Sentiment

Score: 5

Explanation: The document presents a mixed picture with some positive developments (improved net loss, strong cash position) but also negative trends (revenue decline, gross margin decrease, restructuring charges). The company is facing challenges but is also taking steps to address them, resulting in a neutral sentiment.

Positives

• The net loss improved in both Q2 2024 and the first six months of 2024 compared to the same periods in 2023.
• The company has a substantial amount of cash and short-term investments on hand.
• The company is actively working to expand payor coverage for its 10 kHz Therapy for PDN and NSBP.
• The company has completed the integration of manufacturing activities in its Costa Rica facility.

Negatives

• Revenue decreased by 4% in Q2 2024 compared to Q2 2023.
• Gross margin decreased from 68% to 65% in Q2 2024.
• The company incurred a $6.0 million one-time charge due to a supplier contract renegotiation.
• Operating expenses remain high, including restructuring charges.
• The company is still experiencing a net loss, although it has improved year-over-year.

Risks

• The company is subject to macroeconomic conditions that could impact patient decisions to seek elective procedures.
• The company relies on third-party suppliers, which exposes it to supply chain risks and potential inventory obsolescence.
• The company faces significant competition in the neuromodulation market.
• The company's ability to repay its 2025 Notes and Braidwell Term Loans could be adversely impacted by higher interest rates.
• The company's success depends on broad market acceptance of its 10 kHz Therapy and Senza product platform.
• The company may need to raise additional funds in the future, which may not be available on acceptable terms.

Future Outlook

The company expects its cash and cash equivalents, along with anticipated funds from receivables, to be sufficient to fund operations for at least the next 12 months. They plan to continue investing in commercial infrastructure, R&D, and clinical trials. The company may also seek additional funding through equity or debt financings.

Management Comments

• Management believes the superiority of 10 kHz Therapy over traditional SCS therapies will allow them to expand in the global SCS market.
• Management intends to continue to make significant investments in the U.S. commercial infrastructure, including building out a sales organization that targets physician specialties involved in PDN treatment decisions.
• Management believes expanding into new indications, implementing product improvements and continuing to demonstrate the efficacy, safety and cost effectiveness of the 10 kHz Therapy through clinical data are all critical to increasing the adoption of this therapy.

Industry Context

The report highlights Nevro's position in the competitive neuromodulation market, where it faces established players like Medtronic, Boston Scientific, and Abbott Laboratories. The company is focusing on its unique 10 kHz Therapy and expanding into new indications like PDN and NSBP to gain market share. The report also notes the impact of macroeconomic conditions on the medical device industry, including potential delays in elective procedures due to economic pressures.

Comparison to Industry Standards

• Nevro's 10 kHz Therapy is positioned as superior to traditional SCS therapies, which is a key differentiator in the market.
• The company's SENZA-PDN and SENZA-NSRBP studies are presented as robust clinical evidence, which is important for gaining physician and payor acceptance.
• The company's gross margin of 65% is lower than some established medical device companies, which may indicate pricing pressures or higher manufacturing costs.
• The company's continued net losses highlight the challenges of achieving profitability in the competitive medical device market, especially while investing heavily in R&D and commercial expansion.
• Compared to competitors like Medtronic and Boston Scientific, Nevro is a smaller company with a more focused product portfolio, which may present both opportunities and challenges.

Management Changes

Legal Proceedings

• The company is involved in several pending European patent oppositions at the European Patent Office (EPO) initiated by competitors.
• The company is also involved in various legal proceedings, such as employment matters, product liability matters, and professional liability matters.
• The company won an arbitration ruling against Flathead Partners, receiving $0.2 million in damages and control of a patent application.
• The company is cooperating with a civil investigative demand (CID) from the United States Attorneys Office for the Northern District of California related to marketing, promotion and billing practices.

Stakeholder Impact

• Shareholders may be concerned about the revenue decline and gross margin decrease, but encouraged by the improved net loss and strong cash position.
• Employees may be affected by the restructuring efforts, including layoffs.
• Customers and patients may benefit from the company's continued investment in R&D and product improvements.
• Suppliers may be impacted by the company's renegotiation of contracts and efforts to vertically integrate manufacturing.

Next Steps

• The company will continue to invest in its U.S. commercial infrastructure and sales force.
• The company will continue to invest in R&D and conduct clinical trials.
• The company will work to expand payor coverage for its 10 kHz Therapy for PDN and NSBP.
• The company will continue to monitor and manage its supply chain and inventory levels.

Key Dates

Keywords

spinal cord stimulation, neuromodulation, chronic pain, 10 kHz Therapy, Senza, PDN, NSBP, medical devices, restructuring, financial results